COMPANY

Neutrolis, Inc.

Keywords: immunology inflammatory diseases systemic lupus erythematosus SLE (Systemic Lupus) RA - Rheumatoid Arthritis Covid19 NTR1011 NTR-441

Location: Cambridge, MA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Timeline

Jul 15, 2026 Trial start 1: Phase 1a/b Tolerability of NTR-1011 in Healthy Adults and Adult Patients With SLE and RA source ↗
Apr 14, 2021 Trial start 1: Phase 1 Study to Assess Safety, Tolerability, PD, PK, Immunogenicity of IV NTR-441 Solution in Healthy Volunteers and COVID-19 Patients source ↗

Mar 31, 2027 (ESTIMATED) · 1 · Phase 1a/b Tolerability of NTR-1011 in Healthy Adults and Adult Patients With SLE and RA · NCT07237659

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT07237659	Phase 1a/b Tolerability of NTR-1011 in Healthy Adults and Adult Patients With SLE and RA	1	Recruiting	Jul 15, 2026	Mar 31, 2027 (estimated)
NCT04941183	Phase 1 Study to Assess Safety, Tolerability, PD, PK, Immunogenicity of IV NTR-441 Solution in Healthy Volunteers and COVID-19 Patients	1	Terminated	Apr 14, 2021	Dec 12, 2022 (actual)